12/2
03:41 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:00 am
cgem
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Medium
Report
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
11/24
12:08 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.
High
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.
11/22
02:11 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at
Wall Str
High
Report
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at
Wall Str
11/20
11:08 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
11/20
02:10 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was given a new $26.00 price target on by analysts at New Street Research.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) was given a new $26.00 price target on by analysts at New Street Research.
11/20
11:04 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
11/20
07:00 am
cgem
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR E
Low
Report
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR E
11/10
07:00 am
cgem
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
Medium
Report
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
11/6
07:00 am
cgem
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Low
Report
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
11/3
09:11 am
cgem
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
Medium
Report
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
10/25
11:01 am
cgem
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
Low
Report
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
10/12
06:27 pm
cgem
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
Low
Report
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
9/18
06:43 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
9/12
08:03 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
9/12
07:00 am
cgem
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
Medium
Report
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
9/11
08:08 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
9/9
05:30 am
cgem
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Low
Report
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer